Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2121861 | 0.84 | KDM4E (0.53) | KDM4EHSD17B10HPGDALDH1A1MAPK1 | |
| SCHEMBL2123041 | 0.80 | KDM4E (0.33) | KDM4EHSD17B10HPGDALDH1A1LMNA | |
| SCHEMBL2123488 | 0.79 | KDM4E (0.43) | KDM4EHSD17B10HPGDALDH1A1MAPK1 | |
| SCHEMBL2123364 | 0.79 | METTL3 (0.35) | KDM4EHSD17B10HPGDALDH1A1MAPT | |
| SCHEMBL2536526 | 0.78 | KDM4E (0.34) | KDM4EHSD17B10HPGDALDH1A1LMNA | |
| SCHEMBL2512568 | 0.74 | SMN1; SMN2 (0.35) | KDM4EALDH1A1MAPK1SMN1; SMN2MAPT | |
| SCHEMBL2533053 | 0.74 | METTL3 (0.43) | KDM4EHSD17B10HPGDALDH1A1LMNA | |
| SCHEMBL2538398 | 0.73 | PDE8B (0.42) | KDM4EHSD17B10HPGDALDH1A1LMNA | |
| SCHEMBL2122898 | 0.73 | METTL3 (0.43) | KDM4EHSD17B10HPGDALDH1A1 | |
| SCHEMBL2514192 | 0.72 | SMN1; SMN2 (0.34) | KDM4EALDH1A1MAPK1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379550-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | Glaxo Group Limited (GB) | 2011-10-26 | — | — | EP | disclosed |
| US-20110257198-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2011-10-20 | — | — | US | disclosed |
| WO-2010072722-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257198-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, VIPR2 | KDM4E 1459/4885HSD17B10 3769/4885HPGD 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.